Citadel Advisors
DFTX

Citadel Advisors’s Definium Therapeutics DFTX Stock Holding History

Citadel Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.4M Buy
1,688,587
+355,145
+27% +$8.78M 0.01% 1144
2026
Q1 		$25.2M Buy
1,333,442
+1,123,498
+535% +$19.1M ﹤0.01% 2051
2025
Q4 		$2.81M Sell
209,944
-129,494
-38% -$1.6M ﹤0.01% 5292
2025
Q3 		$4M Buy
339,438
+160,834
+90% +$1.5M ﹤0.01% 4761
2025
Q2 		$1.16M Sell
178,604
-234,786
-57% -$1.54M ﹤0.01% 6760
2025
Q1 		$2.42M Buy
413,390
+291,630
+240% +$2.09M ﹤0.01% 5162
2024
Q4 		$847K Buy
121,760
+78,917
+184% +$543K ﹤0.01% 7402
2024
Q3 		$244K Buy
42,843
+25,263
+144% +$176K ﹤0.01% 9737
2024
Q2 		$127K Sell
17,580
-39,740
-69% -$348K ﹤0.01% 10577
2024
Q1 		$539K Buy
57,320
+56,235
+5,183% +$321K ﹤0.01% 8222
2023
Q4 		$3.97K Sell
1,085
-60,603
-98% -$182K ﹤0.01% 13542
2023
Q3 		$193K Buy
+61,688
New +$254K ﹤0.01% 9977
2023
Q2 		– Sell
-14,790
Closed -$51K – 14902
2023
Q1 		$46.9K Sell
14,790
-61,598
-81% -$205K ﹤0.01% 12243
2022
Q4 		$168K Sell
76,388
-10,549
-12% -$29.3K ﹤0.01% 10427
2022
Q3 		$304K Sell
86,937
-29,185
-25% -$280K ﹤0.01% 9553
2022
Q2 		$1.11M Buy
116,122
+36,117
+45% +$457K ﹤0.01% 6777
2022
Q1 		$1.33M Sell
80,005
-30,712
-28% -$533K ﹤0.01% 7024
2021
Q4 		$2.29M Buy
110,717
+92,711
+515% +$2.96M ﹤0.01% 5930
2021
Q3 		$629K Sell
18,006
-3,345
-16% -$145K ﹤0.01% 9313
2021
Q2 		$1.1M Buy
+21,351
New +$1.12M ﹤0.01% 8106

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Citadel Advisors's DFTX Position: Q2 2026 in Review

Citadel Advisors increased its Definium Therapeutics (DFTX) stake by 27% in Q2 2026, buying an estimated $8.78M and bringing the position to 1,688,587 shares worth $79.4M. The position accounts for 0.01% of the portfolio, ranked #1144.

Citadel Advisors first reported a position in DFTX in Q2 2021 and has held it in 20 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Citadel Advisors held 1,688,587 shares of Definium Therapeutics worth $79.4M as of Q2 2026.
  • Citadel Advisors bought 355,145 Definium Therapeutics shares in Q2 2026, an estimated $8.78M.
  • Definium Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #1144 holding.
  • Citadel Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.